Magpale, Nicasio R.

HRN: 22-61-27  Sex: Male

Patient Encounter


Audit Details

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
12/12/2025
LEVOFLOXACIN 5MG/ML, 100ML (VIAL)
12/12/2025
12/18/2025
IV
750mg LD, Then 500mg Q48
750mg LD, Then 500mg Q48
Sepsis, HAP
Checking Final Appropriateness 

Indication:  Empirical Escalation    Type of Infection:  Pneumonia    Compliance to guidelines: Compliant To Guidelines

Initial appropriateness: Yes   

Intervention



Type of Intervention done:

                    

           


Acceptance: